Merck & Company (MRK) 50.95 $MRK
Dow 30 Stock Roundup: Microsoft Launces Surface Book, Merck's Keytruda Approved for Lung Cancer
Swarup Gupta - Zacks Investment Research - Fri Oct 09, 1:59PM CDT
The Dow registered a record winning streak this week, boosted by energy stocks and the Fed's dovish stance.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), ADP: 85.24 (+0.12), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DD: 56.18 (+0.05), MSFT: 47.11 (-0.34), BA: 139.70 (+0.66), CSCO: 27.91 (unch)
This Double-Whammy Sent Merck Shares Notably Lower in September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 9:03AM CDT
MRK data by YCharts . Shares of Big Pharma Merck struggled mightily in September, ending the month lower by 7.5% according to data from S&P Capital IQ . Since August 19, Merck's stock has dropped by almost 17%, wiping out more than $27...
MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Oct 09, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, the American Diabetes Association and actress S. Epatha Merkerson are bringing America's Diabetes Challenge: Get to Your Goals to New Orleans. The program is designed to help African Americans with type 2 diabetes work with their doctor to set and reach their A1C goal. A1C is a person's average blood glucose level over the past 2 to 3 months. The program also encourages African Americans to learn if they are at risk of low blood glucose and how to help reduce that risk.
MRK: 50.95 (-0.07)
Publicis' ZenithOptimedia acquires Frubis in Latin America
M2 - Fri Oct 09, 6:06AM CDT
ZenithOptimedia, a part of communications company Publicis Groupe (Paris
UB), announced on Thursday that it has acquired Frubis, a performance marketing agency in Latin America.
MRK: 50.95 (-0.07), PUB: 16.42 (+0.07)
KEYTRUDA(R) (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Business Wire - Fri Oct 09, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA(R) (pembrolizumab) as a first-line treatment option for adults with advanced melanoma.
MRK: 50.95 (-0.07)
Gilead Is About to Disappoint Investors -- but for All the Right Reasons
George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 8:06PM CDT
After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. The problem is that Wall Street appears to be becoming increasingly...
GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), ABBV: 55.64 (-0.40)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), CORT: 3.74 (-0.05)
Global Animal Health Market Report: 2015 Edition
M2 - Thu Oct 08, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7vrc8c/global_animal) has announced the addition of the "Global Animal Health Market Report: 2015 Edition" report to their offering. The report, Global Animal Health Market analyzes the development of the animal health market, with a focus on its segments including: market for companion animals and food producing animals. The global market along with markets of the U.S., Europe and India are being discussed in the report. Animals like humans also suffer from diseases and hence require proper care from veterinarians, farmers and pet owners. Improving the health and well-being of companion animals, livestock and wild animals and treating them is the foremost objective of animal health industry. Companion animals are the animals that are kept by people for companionship, protection and enjoyment whereas food producing animals are those which are raised in agricultural setting to produce commodities such as food and fiber and thereby serve the purpose of feeding humans. Animal health products, also known as veterinary medicines are pharmaceuticals, vaccines and feed additives used to keep animals healthy. These medicines help companion animals live longer and healthier lives and increase productivity of livestock. Increasing animal meat consumption globally, rising ageing population, improving economic conditions with rise in the global GDP, increasing urban population, faster and cheaper regulatory approvals, increasing scope for Biologics and Oncolytic and improving drought conditions in high plain regions of the U.S., are the major factors contributing to the growth of animal health market. However, the growth of the market has been hindered by certain challenges including major threats from new entrants and generic companies, entrance of other players in food retail space and increased cost of product development. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The three major players in the industry - Zoetis, Merck, Elli Lilly and Sanofi are being profiled, along with their key financials and strategies for growth. Key Topics Covered: 1. Market Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly and Company - Merck and Co - Sanofi - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/7v...bal_animal
ZTS: 42.80 (-0.42), MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab)
Marketwired - Thu Oct 08, 6:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has initiated patient dosing in the company's trial evaluating the combination of two immunotherapies: Dynavax's SD-101 and Merck's (NYSE: MRK) KEYTRUDA(R) (pembrolizumab). The multicenter, open-label trial is enrolling patients with advanced or metastatic melanoma and will investigate the safety and potential efficacy of Dynavax's investigational toll-like receptor 9 (TLR9) agonist, SD-101, in combination with Merck's anti-PD-1 therapy, KEYTRUDA.
DVAX: 23.86 (+0.39), MRK: 50.95 (-0.07)
Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc. for the Discovery and Development of Novel Pain Medications
PR Newswire - Thu Oct 08, 5:00AM CDT
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.
MRK: 50.95 (-0.07), BNO: 17.82 (-0.26)
Global End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Clinical Trials Review H2, 2015
M2 - Thu Oct 08, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tbjjl/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" report to their offering. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Clinical Trial Overview of Top Companies - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Plc - Shire Plc - Sanofi - Pfizer Inc. - Merck & Co., Inc. - DaVita HealthCare Partners Inc. - AbbVie Inc. Clinical Trial Overview of Top Institutes / Government - Isfahan University of Medical Sciences - Shiraz University of Medical Sciences - The National Institute of Allergy and Infectious Diseases - Vanderbilt University - The National Institute of Diabetes and Digestive and Kidney Diseases - University of Alberta - Ahvaz Jundishapur University of Medical Sciences - Centre Hospitalier Universitaire Vaudois - Columbia University - Creighton University For more information visit http://www.researchandmarkets.com/research/7t...age_kidney
SHPG: 200.90 (-1.85), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)
Shares of MRK Down 12.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 07, 9:41AM CDT
SmarTrend identified a Downtrend for Merck (NYSE:MRK) on August 21st, 2015 at $56.70. In approximately 2 months, Merck has returned 12.11% as of today's recent price of $49.83.
MRK: 50.95 (-0.07)
CareSync Secures $18 Million in Series B Funding
Business Wire - Wed Oct 07, 8:15AM CDT
CareSync, the leading provider of software and services for chronic disease management, today announced it has secured $18 million in Series B funding. Round participants include the Merck Global Health Innovation Fund (Merck GHI), Greycroft Partners and Harbert Venture Partners, as well as existing investors Tullis Health Investors, Clearwell Group, CDH Solutions and Travis Bond. The funding will help CareSync expand to meet demand for its services-enabled technology platform, strengthening its leading position in the emerging patient-centered care coordination market.
MRK: 50.95 (-0.07)
Research and Markets: Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
Business Wire - Wed Oct 07, 7:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f6r52/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering.
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93)
Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
M2 - Wed Oct 07, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqs29p/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering. The global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019. The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells. According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market. Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period. Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Oral - Parenteral Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Small Molecules - Biologics Key Vendors - Arbor Pharmaceuticals - Bristol-Myers Squibb - Eisai - F. Hoffmann-La Roche - Merck For more information visit http://www.researchandmarkets.com/research/tqs29p/global
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93)
Global Hospital Acquired Pneumonia (HAP) Pipeline Review, H2 2015 - 15 Companies & 22 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2hplb/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aridis Pharmaceuticals LLC - AstraZeneca Plc - Cardeas Pharma Corp. - Dong-A Socio Group - MedImmune, LLC - Meiji Seika Pharma Co., Ltd. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Motif Bio Plc - Nabriva Therapeutics AG - Savara Inc. - Serendex Pharmaceuticals A/S - Tetraphase Pharmaceuticals Inc. Drug Profiles - (amikacin fosfomycin) - (ceftazidime avibactam sodium) - (ceftolozane sulfate tazobactam sodium) - AA-139 - arbekacin - delafloxacin - eravacycline - iclaprim mesylate - lefamulin - MEDI-3902 - MEDI-4893 - molgramostim - Nu-2 - Panaecin - plazomicin sulfate - pseudomonas VAP vaccine - Pseudomonas aeruginosa vaccine - Qn-2251 - relebactam - tedizolid phosphate - tosatoxumab - vancomycin hydrochloride For more information visit http://www.researchandmarkets.com/research/z2...l_acquired
TTPH: 9.38 (+0.08), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AKAO: 6.06 (+0.09), NBRV: 9.86 (+0.09)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Dow 30 Stock Roundup: Microsoft Launces Surface Book, Merck's Keytruda Approved for Lung Cancer
Swarup Gupta - Zacks Investment Research - Fri Oct 09, 1:59PM CDT
The Dow registered a record winning streak this week, boosted by energy stocks and the Fed's dovish stance.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), ADP: 85.24 (+0.12), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DD: 56.18 (+0.05), MSFT: 47.11 (-0.34), BA: 139.70 (+0.66), CSCO: 27.91 (unch)
This Double-Whammy Sent Merck Shares Notably Lower in September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 9:03AM CDT
MRK data by YCharts . Shares of Big Pharma Merck struggled mightily in September, ending the month lower by 7.5% according to data from S&P Capital IQ . Since August 19, Merck's stock has dropped by almost 17%, wiping out more than $27...
MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Oct 09, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, the American Diabetes Association and actress S. Epatha Merkerson are bringing America's Diabetes Challenge: Get to Your Goals to New Orleans. The program is designed to help African Americans with type 2 diabetes work with their doctor to set and reach their A1C goal. A1C is a person's average blood glucose level over the past 2 to 3 months. The program also encourages African Americans to learn if they are at risk of low blood glucose and how to help reduce that risk.
MRK: 50.95 (-0.07)
Publicis' ZenithOptimedia acquires Frubis in Latin America
M2 - Fri Oct 09, 6:06AM CDT
ZenithOptimedia, a part of communications company Publicis Groupe (Paris
UB), announced on Thursday that it has acquired Frubis, a performance marketing agency in Latin America. MRK: 50.95 (-0.07), PUB: 16.42 (+0.07)
KEYTRUDA(R) (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Business Wire - Fri Oct 09, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA(R) (pembrolizumab) as a first-line treatment option for adults with advanced melanoma.
MRK: 50.95 (-0.07)
Gilead Is About to Disappoint Investors -- but for All the Right Reasons
George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 8:06PM CDT
After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. The problem is that Wall Street appears to be becoming increasingly...
GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), ABBV: 55.64 (-0.40)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), CORT: 3.74 (-0.05)
Global Animal Health Market Report: 2015 Edition
M2 - Thu Oct 08, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7vrc8c/global_animal) has announced the addition of the "Global Animal Health Market Report: 2015 Edition" report to their offering. The report, Global Animal Health Market analyzes the development of the animal health market, with a focus on its segments including: market for companion animals and food producing animals. The global market along with markets of the U.S., Europe and India are being discussed in the report. Animals like humans also suffer from diseases and hence require proper care from veterinarians, farmers and pet owners. Improving the health and well-being of companion animals, livestock and wild animals and treating them is the foremost objective of animal health industry. Companion animals are the animals that are kept by people for companionship, protection and enjoyment whereas food producing animals are those which are raised in agricultural setting to produce commodities such as food and fiber and thereby serve the purpose of feeding humans. Animal health products, also known as veterinary medicines are pharmaceuticals, vaccines and feed additives used to keep animals healthy. These medicines help companion animals live longer and healthier lives and increase productivity of livestock. Increasing animal meat consumption globally, rising ageing population, improving economic conditions with rise in the global GDP, increasing urban population, faster and cheaper regulatory approvals, increasing scope for Biologics and Oncolytic and improving drought conditions in high plain regions of the U.S., are the major factors contributing to the growth of animal health market. However, the growth of the market has been hindered by certain challenges including major threats from new entrants and generic companies, entrance of other players in food retail space and increased cost of product development. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The three major players in the industry - Zoetis, Merck, Elli Lilly and Sanofi are being profiled, along with their key financials and strategies for growth. Key Topics Covered: 1. Market Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly and Company - Merck and Co - Sanofi - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/7v...bal_animal
ZTS: 42.80 (-0.42), MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab)
Marketwired - Thu Oct 08, 6:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has initiated patient dosing in the company's trial evaluating the combination of two immunotherapies: Dynavax's SD-101 and Merck's (NYSE: MRK) KEYTRUDA(R) (pembrolizumab). The multicenter, open-label trial is enrolling patients with advanced or metastatic melanoma and will investigate the safety and potential efficacy of Dynavax's investigational toll-like receptor 9 (TLR9) agonist, SD-101, in combination with Merck's anti-PD-1 therapy, KEYTRUDA.
DVAX: 23.86 (+0.39), MRK: 50.95 (-0.07)
Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc. for the Discovery and Development of Novel Pain Medications
PR Newswire - Thu Oct 08, 5:00AM CDT
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.
MRK: 50.95 (-0.07), BNO: 17.82 (-0.26)
Global End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Clinical Trials Review H2, 2015
M2 - Thu Oct 08, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tbjjl/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" report to their offering. End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H2, 2015" Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Clinical Trial Overview of Top Companies - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca Plc - Shire Plc - Sanofi - Pfizer Inc. - Merck & Co., Inc. - DaVita HealthCare Partners Inc. - AbbVie Inc. Clinical Trial Overview of Top Institutes / Government - Isfahan University of Medical Sciences - Shiraz University of Medical Sciences - The National Institute of Allergy and Infectious Diseases - Vanderbilt University - The National Institute of Diabetes and Digestive and Kidney Diseases - University of Alberta - Ahvaz Jundishapur University of Medical Sciences - Centre Hospitalier Universitaire Vaudois - Columbia University - Creighton University For more information visit http://www.researchandmarkets.com/research/7t...age_kidney
SHPG: 200.90 (-1.85), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71)
Shares of MRK Down 12.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 07, 9:41AM CDT
SmarTrend identified a Downtrend for Merck (NYSE:MRK) on August 21st, 2015 at $56.70. In approximately 2 months, Merck has returned 12.11% as of today's recent price of $49.83.
MRK: 50.95 (-0.07)
CareSync Secures $18 Million in Series B Funding
Business Wire - Wed Oct 07, 8:15AM CDT
CareSync, the leading provider of software and services for chronic disease management, today announced it has secured $18 million in Series B funding. Round participants include the Merck Global Health Innovation Fund (Merck GHI), Greycroft Partners and Harbert Venture Partners, as well as existing investors Tullis Health Investors, Clearwell Group, CDH Solutions and Travis Bond. The funding will help CareSync expand to meet demand for its services-enabled technology platform, strengthening its leading position in the emerging patient-centered care coordination market.
MRK: 50.95 (-0.07)
Research and Markets: Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
Business Wire - Wed Oct 07, 7:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f6r52/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering.
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93)
Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck
M2 - Wed Oct 07, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqs29p/global) has announced the addition of the "Global Glioblastoma Multiforme Therapeutics Market 2015-2019" report to their offering. The global glioblastoma multiforme therapeutics market to grow at a CAGR of 11.94 percent during 2014-2019. The report covers the present scenario and the growth prospects of the global glioblastoma multiforme therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various off-label and branded drugs and the expected launch of vaccines and drug candidates used in the treatment of glioblastoma multiforme. The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, we discuss the major drivers influencing market growth and also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market. The entry of novel therapeutic agents to treat glioblastoma multiforme is a major trend witnessed in the market. The drugs which are currently being used are mostly chemotherapeutic agents that are usually toxic to the cells of the body. These drugs are known to also harm the non-cancerous cells besides destroying the malignant cells. According to the report, the market is expected to grow because of the presence of significant unmet need. This presents an opportunity to the drug makers to develop a therapy to treat glioblastoma multiforme with better efficacy and safety parameters. This in turn will reduce the rate of treatment withdrawal by patients, which would be a positive indicator of growth to the market. Further, the report states that market growth may be hampered because of use of off-label and generic drugs over the branded drugs available in the market. Most of the branded drugs have either lost their patent or will lose their patent during the forecast period. Based on the route of administration of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Oral - Parenteral Based on the type of molecules of the drugs used to treat glioblastoma multiforme, the market is segmented as follows: - Small Molecules - Biologics Key Vendors - Arbor Pharmaceuticals - Bristol-Myers Squibb - Eisai - F. Hoffmann-La Roche - Merck For more information visit http://www.researchandmarkets.com/research/tqs29p/global
MRK: 50.95 (-0.07), BMY: 61.44 (+0.93)
Global Hospital Acquired Pneumonia (HAP) Pipeline Review, H2 2015 - 15 Companies & 22 Drug Profiles
M2 - Wed Oct 07, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2hplb/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aridis Pharmaceuticals LLC - AstraZeneca Plc - Cardeas Pharma Corp. - Dong-A Socio Group - MedImmune, LLC - Meiji Seika Pharma Co., Ltd. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Motif Bio Plc - Nabriva Therapeutics AG - Savara Inc. - Serendex Pharmaceuticals A/S - Tetraphase Pharmaceuticals Inc. Drug Profiles - (amikacin fosfomycin) - (ceftazidime avibactam sodium) - (ceftolozane sulfate tazobactam sodium) - AA-139 - arbekacin - delafloxacin - eravacycline - iclaprim mesylate - lefamulin - MEDI-3902 - MEDI-4893 - molgramostim - Nu-2 - Panaecin - plazomicin sulfate - pseudomonas VAP vaccine - Pseudomonas aeruginosa vaccine - Qn-2251 - relebactam - tedizolid phosphate - tosatoxumab - vancomycin hydrochloride For more information visit http://www.researchandmarkets.com/research/z2...l_acquired
TTPH: 9.38 (+0.08), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), AKAO: 6.06 (+0.09), NBRV: 9.86 (+0.09)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
